Opérations des initiés

EDGAR

Evoke Pharma Inc

Opérations déclarées par les administrateurs, dirigeants et détenteurs de plus de 10 % sur les formulaires 3, 4 et 5 de la SEC, lues dans le XML de chaque dépôt. Les codes et leur libellé sont ceux de la SEC.

Le formulaire 4 doit être déposé dans les deux jours ouvrables suivant l’opération ; les plus récentes peuvent donc ne pas encore être déposées.

Période : opérations datées du 16 nov. 2025 ou après.

Achats sur le marché (code P)
0 opérations, — actions
Ventes sur le marché (code S)
0 opérations, — actions

Les totaux additionnent les opérations déposées listées ; ils comptent ce qui a été déclaré et ne mesurent aucune direction.

Affichage de 1 à 37 sur 37

Opérations des initiés, les plus récentes d’abord, telles que déposées sur les formulaires 3, 4 et 5 de la SEC
DateDéclarantCodeAcquis ou cédéActionsPrix par action, tel que déposéValeur (calculée)Actions détenues aprèsDirecte ou indirecteCase de la règle 10b5-1NotesSource
17 déc. 2025 Déposé le 19 déc. 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Common Stock
Cédé (D)148 15311,00
1 629 683

Calculé : actions × prix par action. Valeur exacte 1629683.00.

0Indirecte (I) See FootnoteNon
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Ouvrir le dépôt 0001104659-25-123156 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 19 déc. 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Titre dérivé: Prefunded Warrants — sous-jacent Common Stock (433 962) — prix d’exercice 0.0001
Cédé (D)433 96210,999
4 773 148,038

Calculé : actions × prix par action. Valeur exacte 4773148.038.

0Indirecte (I) See FootnoteNon
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Ouvrir le dépôt 0001104659-25-123156 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 19 déc. 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Titre dérivé: Series A Common Stock Purchase Warrants — sous-jacent Common Stock (117 019) — prix d’exercice 8.16
Cédé (D)117 0194,71
551 159,49

Calculé : actions × prix par action. Valeur exacte 551159.49.

0Indirecte (I) See FootnoteNon
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Ouvrir le dépôt 0001104659-25-123156 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 19 déc. 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Titre dérivé: Series C Common Stock Purchase Warrants — sous-jacent Common Stock (117 019) — prix d’exercice 8.16
Cédé (D)117 0194,71
551 159,49

Calculé : actions × prix par action. Valeur exacte 551159.49.

0Indirecte (I) See FootnoteNon
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Ouvrir le dépôt 0001104659-25-123156 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 19 déc. 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Titre dérivé: Amended Series A Common Stock Purchase Warrants — sous-jacent Common Stock (158 531) — prix d’exercice 0.01
Cédé (D)158 53110,99
1 742 255,69

Calculé : actions × prix par action. Valeur exacte 1742255.69.

0Indirecte (I) See FootnoteNon
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Ouvrir le dépôt 0001104659-25-123156 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 19 déc. 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Titre dérivé: Amended Series C Common Stock Purchase Warrants — sous-jacent Common Stock (250 627) — prix d’exercice 0.01
Cédé (D)250 62710,99
2 754 390,73

Calculé : actions × prix par action. Valeur exacte 2754390.73.

0Indirecte (I) See FootnoteNon
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Ouvrir le dépôt 0001104659-25-123156 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 218) — prix d’exercice 5.41
Cédé (D)1 218——0Directe (D) Non
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322642 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (5 833) — prix d’exercice 4.45
Cédé (D)5 833——0Directe (D) Non
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322642 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 218) — prix d’exercice 3.453
Cédé (D)1 218——0Directe (D) Non
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322642 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 479) — prix d’exercice 5.41
Cédé (D)1 479——0Directe (D) Non
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322643 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (8 750) — prix d’exercice 4.45
Cédé (D)8 750——0Directe (D) Non
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322643 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 291) — prix d’exercice 3.453
Cédé (D)1 291——0Directe (D) Non
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322643 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 187) — prix d’exercice 5.41
Cédé (D)1 187——0Directe (D) Non
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322641 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (5 833) — prix d’exercice 4.45
Cédé (D)5 833——0Directe (D) Non
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322641 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 187) — prix d’exercice 3.453
Cédé (D)1 187——0Directe (D) Non
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322641 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 250) — prix d’exercice 5.41
Cédé (D)1 250——0Directe (D) Non
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322638 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (5 833) — prix d’exercice 4.45
Cédé (D)5 833——0Directe (D) Non
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322638 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 250) — prix d’exercice 3.453
Cédé (D)1 250——0Directe (D) Non
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322638 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 218) — prix d’exercice 5.41
Cédé (D)1 218——0Directe (D) Non
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322639 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (5 833) — prix d’exercice 4.45
Cédé (D)5 833——0Directe (D) Non
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322639 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 187) — prix d’exercice 3.453
Cédé (D)1 187——0Directe (D) Non
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322639 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025Smeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (5 833) — prix d’exercice 5.51
Cédé (D)5 833——0Directe (D) Non
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322645 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025Smeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 125) — prix d’exercice 3.453
Cédé (D)1 125——0Directe (D) Non
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322645 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025CARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (17 291) — prix d’exercice 5.27
Cédé (D)17 291——0Directe (D) Non
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322644 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025CARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (11 000) — prix d’exercice 4.45
Cédé (D)11 000——0Directe (D) Non
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322644 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025D'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (64 840) — prix d’exercice 5.27
Cédé (D)64 840——0Directe (D) Non
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322637 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025D'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (70 000) — prix d’exercice 4.45
Cédé (D)70 000——0Directe (D) Non
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322637 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025Kowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (17 291) — prix d’exercice 5.27
Cédé (D)17 291——0Directe (D) Non
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322640 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025Kowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (13 000) — prix d’exercice 4.45
Cédé (D)13 000——0Directe (D) Non
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322640 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025PYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (5 833) — prix d’exercice 5.26
Cédé (D)5 833——0Directe (D) Non
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322646 Lu dans le XML du dépôt Contester cette ligne
17 déc. 2025 Déposé le 17 déc. 2025PYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Titre dérivé: Stock Option (Right to Buy) — sous-jacent Common Stock (1 155) — prix d’exercice 3.453
Cédé (D)1 155——0Directe (D) Non
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Ouvrir le dépôt 0001193125-25-322646 Lu dans le XML du dépôt Contester cette ligne
16 déc. 2025 Déposé le 17 déc. 2025Hill Malcolm R Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Cédé (D)133——0Directe (D) Non
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Ouvrir le dépôt 0001193125-25-322642 Lu dans le XML du dépôt Contester cette ligne
16 déc. 2025 Déposé le 17 déc. 2025GARNER CAM L Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Cédé (D)2 330——0Indirecte (I) By Garner Investments, L.L.C.Non
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Ouvrir le dépôt 0001193125-25-322643 Lu dans le XML du dépôt Contester cette ligne
16 déc. 2025 Déposé le 17 déc. 2025Brady Todd C Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Cédé (D)27——0Directe (D) Non
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Ouvrir le dépôt 0001193125-25-322639 Lu dans le XML du dépôt Contester cette ligne
16 déc. 2025 Déposé le 17 déc. 2025CARLSON MARILYN R. Officer: Chief Medical Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Cédé (D)360——0Directe (D) Non
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Ouvrir le dépôt 0001193125-25-322644 Lu dans le XML du dépôt Contester cette ligne
16 déc. 2025 Déposé le 17 déc. 2025D'Onofrio Matthew J Director · Officer: Chief Executive Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Cédé (D)15 509——0Directe (D) Non
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Ouvrir le dépôt 0001193125-25-322637 Lu dans le XML du dépôt Contester cette ligne
16 déc. 2025 Déposé le 17 déc. 2025Kowieski Mark Officer: Chief Financial Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Cédé (D)11 815——0Directe (D) Non
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Ouvrir le dépôt 0001193125-25-322640 Lu dans le XML du dépôt Contester cette ligne

Détenteurs institutionnels (formulaire 13F)

Aucune position du formulaire 13F n’est rattachée à cet émetteur dans le magasin. Un détenteur non encore rattaché ou n’ayant pas encore déposé est absent, pas à zéro.

Détenteurs de 5 % (annexes 13D et 13G)

Les annexes déposées au format structuré de la SEC (depuis fin 2024) sont lues ici. Les précédentes sont en texte libre et ne sont pas lues.

Détenteurs de 5 %, événement le plus récent d’abord, tels que déposés
DétenteurPourcentage de la catégorieActions détenuesDate de l’événementFormulaireSource
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share00,0012/17/2025 Déposé le 19 déc. 2025SCHEDULE 13D/AModification 5Ouvrir le dépôt 0001104659-25-123157 Contester cette ligne
Harkey Wilmot B. Common Stock, par value $0.0001 per share00,0012/17/2025 Déposé le 19 déc. 2025SCHEDULE 13D/AModification 5Ouvrir le dépôt 0001104659-25-123157 Contester cette ligne
Mack Daniel Common Stock, par value $0.0001 per share00,0012/17/2025 Déposé le 19 déc. 2025SCHEDULE 13D/AModification 5Ouvrir le dépôt 0001104659-25-123157 Contester cette ligne
Morgan Stanley Common Stock0.03111/30/2025 Déposé le 5 déc. 2025SCHEDULE 13G/AModification 1Ouvrir le dépôt 0000895421-25-000595 Contester cette ligne
Morgan Stanley Smith Barney LLC Common Stock0.03111/30/2025 Déposé le 5 déc. 2025SCHEDULE 13G/AModification 1Ouvrir le dépôt 0000895421-25-000595 Contester cette ligne
Klein Roger M. Common Stock, par value $0.0001 per share10.5163 000,0011/04/2025 Déposé le 12 nov. 2025SCHEDULE 13DOuvrir le dépôt 0001651175-25-000007 Contester cette ligne
Krieger Charitable Trust Common Stock, par value $0.0001 per share8.3129 000,0011/04/2025 Déposé le 12 nov. 2025SCHEDULE 13DOuvrir le dépôt 0001651175-25-000007 Contester cette ligne
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share15.99268 431,0011/03/2025 Déposé le 4 nov. 2025SCHEDULE 13D/AModification 4Ouvrir le dépôt 0001104659-25-106048 Contester cette ligne
Harkey Wilmot B. Common Stock, par value $0.0001 per share15.99268 431,0011/03/2025 Déposé le 4 nov. 2025SCHEDULE 13D/AModification 4Ouvrir le dépôt 0001104659-25-106048 Contester cette ligne
Mack Daniel Common Stock, par value $0.0001 per share15.99268 431,0011/03/2025 Déposé le 4 nov. 2025SCHEDULE 13D/AModification 4Ouvrir le dépôt 0001104659-25-106048 Contester cette ligne
Morgan Stanley Common Stock10.5163 71808/31/2025 Déposé le 8 sept. 2025SCHEDULE 13GOuvrir le dépôt 0000895421-25-000528 Contester cette ligne
Morgan Stanley Smith Barney LLC Common Stock10.5163 71808/31/2025 Déposé le 8 sept. 2025SCHEDULE 13GOuvrir le dépôt 0000895421-25-000528 Contester cette ligne

Le pourcentage porte sur la catégorie que nomme le dépôt, tel que l’a déclaré le détenteur. Les membres d’un groupe déclarent chacun les actions du groupe ; les lignes ne s’additionnent donc pas.

Ce qui a été lu

2 092 408 dépôts lus, datés du 14 juin 2004 au 13 nov. 2026 : formulaires 3, 3/A, 4, 4/A, 5, 5/A.

Certaines années peuvent être incomplètes tant que l’archive est en cours de lecture. Une année avec peu de dépôts ici n’affirme pas qu’il y en a eu peu.

Dépôts lus, par année de dépôt
Année de dépôtDépôts lus
20151
2016204 322
2017202 494
2018202 048
2019193 638
2020144 184
2021224 474
202240 015
2023199 811
2024185 386
2025235 520
2026254 737

Les dépôts antérieurs à l’obligation du XML par la SEC sont listés, non extraits.

Retour à Evoke Pharma Inc